Staar Surgical CO DEF 14A proxy statements

STAAR Surgical Company reiterates the compelling $28 per share cash value of its proposed merger with Alcon, highlighting significant premiums for stockholders.

STAAR Surgical Company has filed a definitive proxy statement with the SEC regarding a proposed merger transaction, urging stockholders to review all relevant documents before voting.

STAAR Surgical Company has entered into a definitive agreement to be acquired by Alcon for $28.00 per share in cash, a move expected to accelerate EVO ICL adoption and expand global reach.

STAAR Surgical Company has entered a definitive agreement to be acquired by Alcon for $28 per share in cash, representing a significant premium to its recent trading prices.

Alcon has entered into a definitive merger agreement to acquire STAAR Surgical Company for $28.00 per share in cash, valuing the company at approximately $1.5 billion.

STAAR Surgical Company's shareholders are invited to vote on key proposals at the Annual Meeting on June 18, 2025, with proxy materials now available online.

STAAR Surgical's proxy statement reveals strategic shifts, leadership changes, and a focus on navigating macroeconomic headwinds in China while driving growth in other key markets.

STAAR Surgical Company's upcoming annual meeting on June 20, 2024, will address director elections, equity incentive plan amendments, auditor ratification, and executive compensation.

STAAR Surgical is focusing on expanding its EVO ICL technology to more patients globally and creating significant shareholder value, despite macroeconomic challenges in 2023.